GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases

Abstract Background The French PRODIGE 7 trial, published on January 2021, has raised doubts about the specific survival benefit provided by HIPEC with oxaliplatin 460 mg/m2 (30 minutes) for the treatment of peritoneal metastases from colorectal cancer. However, several methodological flaws have bee...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Fernando Pereira, Angel Serrano, Israel Manzanedo, Estibalitz Pérez-Viejo, Santiago González-Moreno, Luis González-Bayón, Alvaro Arjona-Sánchez, Juan Torres, Isabel Ramos, Maria E. Barrios, Pedro Cascales, Rafael Morales, Enrique Boldó, Alfonso García-Fadrique, Xabier Arteaga, Alberto Gutierrez-Calvo, Susana Sánchez-García, Enrique Asensio, Cesar P. Ramírez, Manuel Artiles, Javier Vaqué, Pedro A. Parra, Pedro Villarejo, Cristóbal Muñoz-Casares, Estrella Turienzo, Alicia Calero, Isabel Jaén Torrejimeno, Isabel Prieto, Julio Galindo, Vicente Borrego, Manuel E. Marcello, Cristina Rihuete, Joaquin Carrasco, Luis Gomez-Quiles
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	BMC 2022-05-01
Σειρά:	BMC Cancer
Θέματα:	HIPEC Peritoneal carcinomatosis Peritoneal metastases Colon cancer
Διαθέσιμο Online:	https://doi.org/10.1186/s12885-022-09572-7
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!